Navidea Biopharmaceuticals Inc (NAVB) stock has risen 2.77% over the past week and gets a Bearish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With NAVB Stock Today?
Navidea Biopharmaceuticals Inc (NAVB) stock has gained 4% while the S&P 500 is lower by -1.55% as of 12:06 PM on Thursday, Feb 25. NAVB is higher by $0.10 from the previous closing price of $2.50 on volume of 274,040 shares. Over the past year the S&P 500 has risen 23.53% while NAVB is higher by 168.04%. NAVB lost -$0.52 per share in the over the last 12 months.
To screen for more stocks like Navidea Biopharmaceuticals Inc click here.
More About Navidea Biopharmaceuticals Inc
Navidea Biopharmaceuticals Inc is a biotechnology company specialized in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.
Click Here to get the full Stock Score Report on Navidea Biopharmaceuticals Inc (NAVB) Stock.
